CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TFDP2 (ImmuneEditome ID:7029)

1. Gene summary of enriched editing regions for TFDP2

check button Gene summary
Gene informationGene symbol

TFDP2

Gene ID

7029

GeneSynonymsDP2
GeneCytomap

3q23

GeneTypeprotein-coding
GeneDescriptiontranscription factor Dp-2|transcription factor Dp-2 (E2F dimerization partner 2)
GeneModificationdate20230517
UniprotIDQ14188;C9JTZ9;C9J977;C9JNB6;C9JCY5;C9J5D5;C9J872;F8WAY9;C9J461
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:141945173-141945343:-ENST00000489671.4ENSG00000114126.16TFDP2UTR3AluSpchr3:141945173-141945343:-.alignment
chr3:141945173-141945343:-ENST00000499676.4ENSG00000114126.16TFDP2UTR3AluSpchr3:141945173-141945343:-.alignment
chr3:141946736-141950128:-ENST00000489671.4ENSG00000114126.16TFDP2UTR3AluJb,AluSx,AluSg,AluSc8,L2b,AluYchr3:141946736-141950128:-.alignment
chr3:141946736-141950128:-ENST00000499676.4ENSG00000114126.16TFDP2UTR3AluJb,AluSx,AluSg,AluSc8,L2b,AluYchr3:141946736-141950128:-.alignment
chr3:141975003-141975233:-ENST00000492919.1ENSG00000114126.16TFDP2ncRNA_intronicCharlie10b,AluSx4chr3:141975003-141975233:-.alignment
chr3:141975003-141975233:-ENST00000493204.1ENSG00000114126.16TFDP2ncRNA_intronicCharlie10b,AluSx4chr3:141975003-141975233:-.alignment
chr3:142018510-142019242:-ENST00000464782.4ENSG00000114126.16TFDP2ncRNA_intronicAluSq2,L1MC5,AluJrchr3:142018510-142019242:-.alignment
chr3:142018510-142019242:-ENST00000471095.4ENSG00000114126.16TFDP2ncRNA_intronicAluSq2,L1MC5,AluJrchr3:142018510-142019242:-.alignment
chr3:142018510-142019242:-ENST00000476617.4ENSG00000114126.16TFDP2ncRNA_intronicAluSq2,L1MC5,AluJrchr3:142018510-142019242:-.alignment
chr3:142018510-142019242:-ENST00000495095.5ENSG00000114126.16TFDP2ncRNA_intronicAluSq2,L1MC5,AluJrchr3:142018510-142019242:-.alignment
chr3:142023276-142024043:-ENST00000464782.4ENSG00000114126.16TFDP2ncRNA_intronicAluSz,AluJbchr3:142023276-142024043:-.alignment
chr3:142023276-142024043:-ENST00000471095.4ENSG00000114126.16TFDP2ncRNA_intronicAluSz,AluJbchr3:142023276-142024043:-.alignment
chr3:142023276-142024043:-ENST00000476617.4ENSG00000114126.16TFDP2ncRNA_intronicAluSz,AluJbchr3:142023276-142024043:-.alignment
chr3:142023276-142024043:-ENST00000495095.5ENSG00000114126.16TFDP2ncRNA_intronicAluSz,AluJbchr3:142023276-142024043:-.alignment
chr3:142047868-142048057:-ENST00000464782.4ENSG00000114126.16TFDP2ncRNA_intronicAluSqchr3:142047868-142048057:-.alignment
chr3:142047868-142048057:-ENST00000476617.4ENSG00000114126.16TFDP2ncRNA_intronicAluSqchr3:142047868-142048057:-.alignment
chr3:142047868-142048057:-ENST00000495095.5ENSG00000114126.16TFDP2ncRNA_intronicAluSqchr3:142047868-142048057:-.alignment
chr3:142090594-142091552:-ENST00000464782.4ENSG00000114126.16TFDP2ncRNA_intronicCharlie17a,AluSx,AluSx1chr3:142090594-142091552:-.alignment
chr3:142090594-142091552:-ENST00000476617.4ENSG00000114126.16TFDP2ncRNA_intronicCharlie17a,AluSx,AluSx1chr3:142090594-142091552:-.alignment
chr3:142090594-142091552:-ENST00000495095.5ENSG00000114126.16TFDP2ncRNA_intronicCharlie17a,AluSx,AluSx1chr3:142090594-142091552:-.alignment


Top

2. Tumor-specific enriched editing regions for TFDP2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:141946736-141950128:-BRCAEER7.0755e-32image
ENSG00000114126.16,TFDP2BRCAEAG1.5768e-29image
chr3:141946736-141950128:-COADEER1.1205e-08image
ENSG00000114126.16,TFDP2COADEAG1.6393e-06image
chr3:141946736-141950128:-HNSCEER3.2889e-05image
ENSG00000114126.16,TFDP2HNSCEAG2.9214e-04image
chr3:141946736-141950128:-KIRCEER8.5275e-15image
ENSG00000114126.16,TFDP2KIRCEAG2.0399e-09image
chr3:141946736-141950128:-LUSCEER2.6448e-04image
ENSG00000114126.16,TFDP2LUSCEAG3.4483e-03image
chr3:141946736-141950128:-PRADEER3.6717e-05image
ENSG00000114126.16,TFDP2PRADEAG4.1100e-07image
chr3:141946736-141950128:-THCAEER8.3882e-11image
ENSG00000114126.16,TFDP2THCAEAG1.7514e-07image
chr3:141946736-141950128:-UCECEER8.5729e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:141946736-141950128:-BLCAPathEER2.5655e-024.0349e-030.1889image
chr3:141946736-141950128:-KIRCPathEER3.3808e-041.8816e-050.1945image
ENSG00000114126.16,TFDP2KIRPPathEAG1.1556e-029.9345e-040.2066image
chr3:141946736-141950128:-KIRPPathEER5.3130e-034.1298e-040.2239image
chr3:141946736-141950128:-THCAPathEER6.2699e-038.7042e-040.1495image
ENSG00000114126.16,TFDP2THCAPathEAG6.3927e-039.2202e-040.1479image
ENSG00000114126.16,TFDP2UVMCliEAG3.8475e-021.4775e-02-0.3876image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr3:141946736-141950128:-PCPGEER2.0693e-023.7967e-025.4442e+06image

Top

3. Enriched editing regions and immune related genes for TFDP2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:141946736-141950128:-LGGEERENSG00000114126,TFDP2-0.54697.9693e-356.2121e-29-0.4618imageNNTFDP2T_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000171681,ATF7IP-0.48004.6966e-262.7938e-27-0.4492imageNNNAT_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000149639,SOGA1-0.48221.0189e-251.0899e-22-0.4110imageNNNAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000171316,CHD7-0.47077.6569e-252.2253e-24-0.4256imageNNCHD7Macrophages_M1GSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000124766,SOX4-0.46094.8060e-241.4377e-22-0.4099imageNNSOX4Macrophages_M1GSVA_HALLMARK_G2M_CHECKPOINT
chr3:141946736-141950128:-LGGEERENSG00000068654,POLR1A-0.46321.5130e-237.6165e-24-0.4210imageNNNAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000106261,ZKSCAN1-0.45667.3955e-231.1480e-25-0.4363imageNNNAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000197013,ZNF429-0.45687.6087e-236.9487e-25-0.4298imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000198315,ZKSCAN8-0.45172.0205e-227.7546e-26-0.4377imageNNNANeutrophilsGSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000256771,ZNF253-0.45162.7606e-221.8207e-22-0.4090imageNNNAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000114126,TFDP2-0.54697.9693e-356.2121e-29-0.4618imageNNTFDP2T_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000171681,ATF7IP-0.48004.6966e-262.7938e-27-0.4492imageNNNAT_cells_CD8GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000149639,SOGA1-0.48221.0189e-251.0899e-22-0.4110imageNNNAMonocytesGSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000171316,CHD7-0.47077.6569e-252.2253e-24-0.4256imageNNCHD7Macrophages_M1GSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000124766,SOX4-0.46094.8060e-241.4377e-22-0.4099imageNNSOX4Macrophages_M1GSVA_HALLMARK_G2M_CHECKPOINT
chr3:141946736-141950128:-LGGEERENSG00000068654,POLR1A-0.46321.5130e-237.6165e-24-0.4210imageNNNAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000106261,ZKSCAN1-0.45667.3955e-231.1480e-25-0.4363imageNNNAMacrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:141946736-141950128:-LGGEERENSG00000197013,ZNF429-0.45687.6087e-236.9487e-25-0.4298imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000198315,ZKSCAN8-0.45172.0205e-227.7546e-26-0.4377imageNNNANeutrophilsGSVA_HALLMARK_MYOGENESIS
chr3:141946736-141950128:-LGGEERENSG00000256771,ZNF253-0.45162.7606e-221.8207e-22-0.4090imageNNNAT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS

More results



Top

4. Enriched editing regions and immune related splicing for TFDP2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:141946736-141950128:-
COADEERIRENSG00000135473.10chr1256326312:56326959:56327363:563276310.24581.6499e-028.0196e-110.4255imageNNNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr3:141946736-141950128:-
COADEERIRENSG00000145020.10chr349416777:49417367:49417614:49417718-0.20462.9032e-022.1382e-11-0.4760imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr3:141946736-141950128:-
COADEERMEXENSG00000105053.6chr1949989695:49989771:49992859:49992952:49997503:49997570:50000789:500008540.25462.1218e-022.5355e-110.4224imageNNNAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000114126.16,TFDP2
KIRPEAGIRENSG00000226742.3chr1879966611:79966674:79968092:79968183-0.24512.7922e-043.1460e-10-0.4054imageNACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;KHDRBS2;LARP4B;LIN28;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TRA2A;U2AF1;U2AF2;UPF1;ZNF184HSBP1L1T_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr3:141946736-141950128:-
KIRPEERA3ENSG00000173947.9chr1111346909:111347049:111350105:111350223:111348515:1113502230.22612.0734e-032.9607e-090.4079imageNNNAMast_cells_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr3:141946736-141950128:-
KIRPEERESENSG00000173947.9chr1111346909:111347049:111348515:111348646:111350105:111350223-0.22612.0734e-032.9607e-09-0.4079imageNNNAMast_cells_restingGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr3:141946736-141950128:-
KIRPEERIRENSG00000148688.9chr1090902242:90903276:90905301:90905638-0.29217.2376e-061.5851e-09-0.4085imageNNNAMast_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr3:141946736-141950128:-
OVEERIRENSG00000131981.11chr1455137368:55137694:55138044:55138368-0.26491.0667e-049.7011e-11-0.4212imageNNLGALS3Macrophages_M1GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr3:141946736-141950128:-
OVEERESENSG00000165006.9chr934220907:34220948:34234215:34234340:34241184:34241577-0.21211.4439e-022.3640e-29-0.6017imageNNNAGSVA_HALLMARK_HEME_METABOLISM
ENSG00000114126.16,TFDP2
OVEAGIRENSG00000126456.11chr1949664673:49664846:49665483:49665613-0.19932.2536e-022.3607e-15-0.4699imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184IRF3Dendritic_cells_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for TFDP2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:141946736-141950128:-ACCEERPlasma_cells4.0651e-020.2608image
chr3:141946736-141950128:-BLCAEERB_cells_memory1.4129e-03-0.2102image
ENSG00000114126.16,TFDP2BLCAEAGB_cells_memory3.9393e-03-0.1752image
chr3:141946736-141950128:-BRCAEERB_cells_naive1.0268e-05-0.1437image
ENSG00000114126.16,TFDP2BRCAEAGT_cells_CD81.0017e-02-0.0826image
chr3:141946736-141950128:-CESCEERT_cells_CD82.3721e-020.1535image
ENSG00000114126.16,TFDP2CESCEAGT_cells_CD4_memory_activated1.5960e-030.2035image
chr3:141946736-141950128:-CHOLEERNK_cells_resting2.1138e-02-0.4679image
chr3:141946736-141950128:-COADEERT_cells_CD81.8973e-030.2042image
ENSG00000114126.16,TFDP2COADEAGMacrophages_M02.1146e-02-0.1481image
chr3:141946736-141950128:-ESCAEERNeutrophils6.7548e-040.2693image
ENSG00000114126.16,TFDP2ESCAEAGNeutrophils6.5349e-040.2700image
chr3:141946736-141950128:-GBMEERT_cells_regulatory_(Tregs)3.1043e-020.1824image
ENSG00000114126.16,TFDP2GBMEAGT_cells_follicular_helper2.8464e-02-0.1807image
chr3:141946736-141950128:-HNSCEERPlasma_cells1.3625e-03-0.1829image
ENSG00000114126.16,TFDP2HNSCEAGMacrophages_M23.1835e-040.2012image
chr3:141946736-141950128:-KICHEEREosinophils1.1996e-030.4184image
ENSG00000114126.16,TFDP2KICHEAGEosinophils9.2096e-040.4136image
chr3:141946736-141950128:-KIRCEERT_cells_CD83.9677e-050.2166image
chr3:141946736-141950128:-KIRPEERNK_cells_resting3.5648e-020.1272image
ENSG00000114126.16,TFDP2KIRPEAGNK_cells_resting4.6324e-030.1691image
chr3:141946736-141950128:-LAMLEERT_cells_CD4_memory_resting4.3662e-04-0.2985image
ENSG00000114126.16,TFDP2LAMLEAGT_cells_CD4_memory_resting5.3751e-04-0.2930image
chr3:141946736-141950128:-LGGEEREosinophils1.3698e-050.1891image
ENSG00000114126.16,TFDP2LGGEAGEosinophils5.2205e-070.2167image
chr3:141946736-141950128:-LIHCEERT_cells_CD4_memory_resting2.0779e-02-0.2298image
ENSG00000114126.16,TFDP2LIHCEAGDendritic_cells_resting2.2389e-020.1766image
chr3:141946736-141950128:-LUADEERT_cells_CD4_memory_activated2.7027e-020.1159image
ENSG00000114126.16,TFDP2LUADEAGNeutrophils1.8311e-020.1199image
chr3:141946736-141950128:-LUSCEERT_cells_CD4_memory_activated2.4093e-030.1571image
ENSG00000114126.16,TFDP2LUSCEAGMast_cells_resting1.0985e-02-0.1287image
chr3:141946736-141950128:-MESOEERNK_cells_activated7.8560e-030.3346image
ENSG00000114126.16,TFDP2MESOEAGT_cells_CD86.8957e-03-0.3202image
chr3:141946736-141950128:-OVEERT_cells_CD81.1142e-030.1911image
ENSG00000114126.16,TFDP2OVEAGT_cells_CD89.6692e-040.1931image
chr3:141946736-141950128:-PAADEERT_cells_CD84.0646e-02-0.2031image
ENSG00000114126.16,TFDP2PAADEAGMast_cells_activated4.5830e-02-0.1842image
ENSG00000114126.16,TFDP2PCPGEAGNK_cells_resting2.8970e-02-0.1733image
chr3:141946736-141950128:-PRADEERMacrophages_M21.0129e-020.1172image
ENSG00000114126.16,TFDP2PRADEAGMacrophages_M21.7748e-020.1071image
chr3:141946736-141950128:-SARCEERMast_cells_resting2.4252e-03-0.2182image
chr3:141946736-141950128:-SKCMEERT_cells_CD83.3523e-050.2269image
ENSG00000114126.16,TFDP2SKCMEAGT_cells_CD82.8495e-030.1602image
chr3:141946736-141950128:-STADEERT_cells_CD4_memory_activated3.7634e-030.1552image
ENSG00000114126.16,TFDP2STADEAGT_cells_CD4_memory_activated2.5444e-030.1613image
chr3:141946736-141950128:-TGCTEERMacrophages_M24.7794e-06-0.4436image
ENSG00000114126.16,TFDP2TGCTEAGT_cells_regulatory_(Tregs)1.0687e-02-0.2323image
chr3:141946736-141950128:-THCAEERT_cells_regulatory_(Tregs)3.3720e-070.2271image
ENSG00000114126.16,TFDP2THCAEAGT_cells_regulatory_(Tregs)2.2664e-070.2290image
chr3:141946736-141950128:-THYMEERMacrophages_M11.1676e-080.5172image
ENSG00000114126.16,TFDP2THYMEAGT_cells_CD4_memory_resting4.5521e-060.4196image
chr3:141946736-141950128:-UCECEERT_cells_CD4_memory_activated2.5352e-02-0.1961image
ENSG00000114126.16,TFDP2UCECEAGPlasma_cells3.6093e-02-0.1691image
chr3:141946736-141950128:-UCSEERT_cells_CD4_memory_activated6.4175e-030.3881image
ENSG00000114126.16,TFDP2UCSEAGB_cells_naive2.4033e-02-0.3126image
chr3:141946736-141950128:-UVMEERNK_cells_resting2.8211e-02-0.4147image
ENSG00000114126.16,TFDP2UVMEAGT_cells_CD84.5846e-03-0.4445image


Top

6. Enriched editing regions and immune gene sets for TFDP2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr3:141946736-141950128:-HNSCEER3.0958e-02image4.0383e-040.2016image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr3:141946736-141950128:-BRCAEER4.7654e-060.14901.7269e-030.10241.1885e-020.08221.4119e-040.1242image
chr3:141946736-141950128:-LUADEER1.8049e-040.19511.7094e-020.12493.8989e-040.18493.9865e-110.3372image
chr3:141946736-141950128:-STADEER8.6110e-060.23632.0215e-020.12467.0285e-050.21182.0172e-040.1983image
ENSG00000114126.16,TFDP2STADEAG2.3777e-060.24981.1817e-020.13484.3034e-050.21746.1624e-040.1827image
ENSG00000114126.16,TFDP2UVMEAG1.9848e-04-0.56173.3419e-04-0.54501.2007e-05-0.63894.3149e-04-0.5364image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000114126.16,TFDP2ACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.3060e-04-0.4210image
chr3:141946736-141950128:-ACCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.8031e-03-0.3403image
chr3:141946736-141950128:-BLCAGSVA_HALLMARK_HYPOXIAEER1.7454e-040.2461image
ENSG00000114126.16,TFDP2BLCAGSVA_HALLMARK_HYPOXIAEAG1.2277e-020.1525image
chr3:141946736-141950128:-BRCAGSVA_HALLMARK_GLYCOLYSISEER1.7805e-160.2649image
ENSG00000114126.16,TFDP2BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.5094e-080.1777image
chr3:141946736-141950128:-CESCGSVA_HALLMARK_COMPLEMENTEER4.6812e-040.2355image
ENSG00000114126.16,TFDP2CESCGSVA_HALLMARK_COMPLEMENTEAG3.0316e-040.2322image
ENSG00000114126.16,TFDP2CHOLGSVA_HALLMARK_COAGULATIONEAG7.3690e-03-0.4871image
chr3:141946736-141950128:-CHOLGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.9324e-02-0.4739image
chr3:141946736-141950128:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.6688e-05-0.2803image
ENSG00000114126.16,TFDP2COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.9704e-05-0.2491image
chr3:141946736-141950128:-ESCAGSVA_HALLMARK_P53_PATHWAYEER2.0300e-030.2452image
ENSG00000114126.16,TFDP2ESCAGSVA_HALLMARK_P53_PATHWAYEAG1.3266e-030.2548image
chr3:141946736-141950128:-GBMGSVA_HALLMARK_HYPOXIAEER2.1618e-030.2571image
ENSG00000114126.16,TFDP2GBMGSVA_HALLMARK_HYPOXIAEAG2.3082e-030.2495image
chr3:141946736-141950128:-HNSCGSVA_HALLMARK_HYPOXIAEER1.5815e-050.2448image
ENSG00000114126.16,TFDP2HNSCGSVA_HALLMARK_COAGULATIONEAG2.8549e-060.2598image
ENSG00000114126.16,TFDP2KICHGSVA_HALLMARK_ANGIOGENESISEAG3.9344e-020.2646image
chr3:141946736-141950128:-KICHGSVA_HALLMARK_SPERMATOGENESISEER2.4577e-02-0.2976image
chr3:141946736-141950128:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.1182e-050.2194image
ENSG00000114126.16,TFDP2KIRCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.7503e-030.1642image
ENSG00000114126.16,TFDP2KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.2686e-04-0.2011image
chr3:141946736-141950128:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER8.2838e-06-0.2661image
chr3:141946736-141950128:-LAMLGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER3.5288e-070.4216image
ENSG00000114126.16,TFDP2LAMLGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.2884e-070.4263image
chr3:141946736-141950128:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3944e-25-0.4337image
ENSG00000114126.16,TFDP2LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0035e-20-0.3871image
ENSG00000114126.16,TFDP2LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.7714e-030.2022image
chr3:141946736-141950128:-LIHCGSVA_HALLMARK_PEROXISOMEEER5.3927e-030.2749image
chr3:141946736-141950128:-LUADGSVA_HALLMARK_HYPOXIAEER3.9865e-110.3372image
ENSG00000114126.16,TFDP2LUADGSVA_HALLMARK_HYPOXIAEAG7.3713e-090.2886image
ENSG00000114126.16,TFDP2LUSCGSVA_HALLMARK_HYPOXIAEAG9.1995e-040.1672image
chr3:141946736-141950128:-LUSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.1092e-03-0.1531image
ENSG00000114126.16,TFDP2MESOGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG2.0039e-030.3631image
chr3:141946736-141950128:-MESOGSVA_HALLMARK_MYC_TARGETS_V2EER6.2007e-030.3439image
chr3:141946736-141950128:-OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.5801e-070.3030image
ENSG00000114126.16,TFDP2OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.0470e-080.3187image
chr3:141946736-141950128:-PAADGSVA_HALLMARK_SPERMATOGENESISEER1.4614e-02-0.2412image
ENSG00000114126.16,TFDP2PCPGGSVA_HALLMARK_DNA_REPAIREAG2.7489e-03-0.2360image
chr3:141946736-141950128:-PCPGGSVA_HALLMARK_SPERMATOGENESISEER9.2598e-03-0.2240image
ENSG00000114126.16,TFDP2PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2044e-050.1963image
chr3:141946736-141950128:-PRADGSVA_HALLMARK_DNA_REPAIREER5.1865e-100.2784image
chr3:141946736-141950128:-READGSVA_HALLMARK_APICAL_SURFACEEER3.4327e-020.2285image
ENSG00000114126.16,TFDP2READGSVA_HALLMARK_APICAL_SURFACEEAG2.6683e-020.2349image
ENSG00000114126.16,TFDP2SARCGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG2.2373e-020.1539image
chr3:141946736-141950128:-SARCGSVA_HALLMARK_COMPLEMENTEER3.3080e-060.3292image
chr3:141946736-141950128:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.1649e-080.2898image
ENSG00000114126.16,TFDP2SKCMGSVA_HALLMARK_APOPTOSISEAG6.1785e-060.2406image
chr3:142090594-142091552:-STADGSVA_HALLMARK_MITOTIC_SPINDLEEER3.0451e-02-0.2708image
chr3:141946736-141950128:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.7731e-080.2900image
ENSG00000114126.16,TFDP2STADGSVA_HALLMARK_GLYCOLYSISEAG1.9200e-070.2747image
chr3:141946736-141950128:-TGCTGSVA_HALLMARK_UV_RESPONSE_DNEER4.8623e-06-0.4432image
ENSG00000114126.16,TFDP2TGCTGSVA_HALLMARK_KRAS_SIGNALING_DNEAG5.7559e-04-0.3098image
ENSG00000114126.16,TFDP2THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.7257e-140.3286image
chr3:141946736-141950128:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER7.9166e-120.3013image
chr3:141946736-141950128:-THYMGSVA_HALLMARK_G2M_CHECKPOINTEER2.3497e-11-0.5897image
ENSG00000114126.16,TFDP2THYMGSVA_HALLMARK_E2F_TARGETSEAG1.8018e-06-0.4353image
chr3:141946736-141950128:-UCECGSVA_HALLMARK_PEROXISOMEEER4.4831e-030.2478image
ENSG00000114126.16,TFDP2UCSGSVA_HALLMARK_MYOGENESISEAG6.5655e-04-0.4572image
chr3:141946736-141950128:-UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.9224e-040.5131image
chr3:141946736-141950128:-UVMGSVA_HALLMARK_G2M_CHECKPOINTEER3.1594e-02-0.4070image
ENSG00000114126.16,TFDP2UVMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.1010e-05-0.6076image
chr3:141945173-141945343:-UVMGSVA_HALLMARK_UV_RESPONSE_DNEER2.8334e-02-0.4899image


Top

7. Enriched editing regions and drugs for TFDP2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000114126.16,TFDP2ACCBAY.61.3606EAG8.3255e-040.3852image
chr3:141946736-141950128:-ACCAS601245EER3.8948e-030.3615image
chr3:141946736-141950128:-BLCABX.795EER3.4080e-04-0.2352image
ENSG00000114126.16,TFDP2BLCAJNJ.26854165EAG9.7093e-04-0.2000image
ENSG00000114126.16,TFDP2BRCABMS.708163EAG5.4156e-04-0.1109image
chr3:141946736-141950128:-BRCAA.770041EER7.2716e-06-0.1463image
ENSG00000114126.16,TFDP2CESCCI.1040EAG2.4514e-03-0.1955image
chr3:141946736-141950128:-CESCCI.1040EER8.0449e-04-0.2259image
chr3:141946736-141950128:-CHOLA.443654EER1.8829e-03-0.6013image
chr3:141946736-141950128:-COADABT.888EER7.1669e-03-0.1773image
ENSG00000114126.16,TFDP2COADMG.132EAG5.0164e-030.1798image
chr3:141946736-141950128:-ESCABMS.708163EER1.0298e-03-0.2603image
ENSG00000114126.16,TFDP2ESCABMS.708163EAG4.5182e-04-0.2775image
chr3:141946736-141950128:-GBMABT.263EER6.1418e-030.2305image
ENSG00000114126.16,TFDP2GBMEHT.1864EAG7.1310e-030.2211image
ENSG00000114126.16,TFDP2HNSCBexaroteneEAG5.2256e-06-0.2531image
chr3:141946736-141950128:-HNSCCI.1040EER9.4008e-06-0.2511image
chr3:141946736-141950128:-KICHABT.888EER3.3823e-04-0.4582image
ENSG00000114126.16,TFDP2KICHABT.888EAG2.6115e-02-0.2848image
chr3:141946736-141950128:-KIRCCamptothecinEER5.6395e-06-0.2386image
ENSG00000114126.16,TFDP2KIRCBI.D1870EAG1.8715e-040.1954image
chr3:141946736-141950128:-KIRPA.770041EER1.0105e-06-0.2914image
ENSG00000114126.16,TFDP2KIRPA.770041EAG2.3150e-07-0.3042image
ENSG00000114126.16,TFDP2LAMLAG.014699EAG1.1398e-050.3665image
chr3:141946736-141950128:-LAMLAG.014699EER2.3899e-060.3932image
chr3:141946736-141950128:-LGGBAY.61.3606EER7.0454e-170.3542image
ENSG00000114126.16,TFDP2LGGBAY.61.3606EAG1.8522e-160.3484image
ENSG00000114126.16,TFDP2LIHCDoxorubicinEAG3.6477e-03-0.2238image
chr3:141946736-141950128:-LIHCCEP.701EER4.1254e-020.2035image
ENSG00000114126.16,TFDP2LUADCI.1040EAG3.0685e-04-0.1825image
chr3:141946736-141950128:-LUADBMS.509744EER1.0818e-05-0.2284image
chr3:141946736-141950128:-LUSCAP.24534EER1.6674e-030.1627image
ENSG00000114126.16,TFDP2LUSCJNK.9LEAG3.3341e-03-0.1483image
ENSG00000114126.16,TFDP2MESOMetforminEAG1.0880e-020.3026image
chr3:141946736-141950128:-MESOJW.7.52.1EER3.6873e-02-0.2657image
ENSG00000114126.16,TFDP2OVBMS.509744EAG1.9359e-14-0.4301image
chr3:141946736-141950128:-OVBMS.509744EER4.5781e-14-0.4251image
chr3:141946736-141950128:-PAADAZ628EER2.8177e-02-0.2265image
ENSG00000114126.16,TFDP2PAADAICAREAG6.4076e-03-0.2496image
ENSG00000114126.16,TFDP2PCPGMethotrexateEAG4.6701e-05-0.3170image
chr3:141946736-141950128:-PCPGMethotrexateEER9.9834e-05-0.3298image
chr3:141946736-141950128:-PRADEmbelinEER2.7659e-080.2499image
ENSG00000114126.16,TFDP2PRADEmbelinEAG3.3422e-040.1614image
chr3:141946736-141950128:-READFH535EER5.4141e-05-0.4211image
ENSG00000114126.16,TFDP2READFH535EAG2.3286e-06-0.4767image
ENSG00000114126.16,TFDP2SARCBleomycinEAG2.5682e-040.2441image
chr3:141946736-141950128:-SARCEHT.1864EER3.1558e-040.2579image
chr3:141946736-141950128:-SKCMCGP.082996EER3.1399e-05-0.2277image
ENSG00000114126.16,TFDP2SKCMCGP.082996EAG1.4964e-03-0.1703image
ENSG00000114126.16,TFDP2STADCCT007093EAG2.8835e-090.3115image
chr3:141946736-141950128:-STADCCT007093EER1.5253e-080.2979image
chr3:141946736-141950128:-TGCTLenalidomideEER2.0483e-06-0.4586image
ENSG00000114126.16,TFDP2TGCTJNK.Inhibitor.VIIIEAG8.4296e-04-0.3008image
ENSG00000114126.16,TFDP2THCACI.1040EAG8.7857e-24-0.4288image
chr3:141946736-141950128:-THCAEmbelinEER6.1858e-260.4494image
chr3:141946736-141950128:-THYMGW.441756EER4.0309e-14-0.6490image
ENSG00000114126.16,TFDP2THYMDoxorubicinEAG9.7435e-080.4800image
ENSG00000114126.16,TFDP2UCECA.770041EAG3.5712e-05-0.3266image
chr3:141946736-141950128:-UCECGDC0941EER1.6321e-030.2736image
ENSG00000114126.16,TFDP2UCSEmbelinEAG6.7855e-040.4561image
chr3:141946736-141950128:-UCSEmbelinEER2.2381e-050.5712image
ENSG00000114126.16,TFDP2UVMAMG.706EAG3.6574e-040.5420image
chr3:141946736-141950128:-UVMBMS.708163EER5.2325e-030.5131image
chr3:141945173-141945343:-UVMJNK.9LEER2.4464e-020.5009image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType